Insights into Chimeric Antigen Receptor Therapy for Chronic Lymphoblastic Leukemia

Mohamad Hamieh; Michel Sadelain

doi:10.1016/j.molmed.2018.06.007

Insights into Chimeric Antigen Receptor Therapy for Chronic Lymphoblastic Leukemia

Trends Mol Med. 2018 Sep;24(9):729-731. doi: 10.1016/j.molmed.2018.06.007. Epub 2018 Jul 4.

Authors

Mohamad Hamieh¹, Michel Sadelain²

Affiliations

¹ Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
² Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address: m-sadelain@ski.mskcc.org.

PMID: 30149852
DOI: 10.1016/j.molmed.2018.06.007

Abstract

In a recent study, Fraietta and colleagues identified chimeric antigen receptor (CAR) T cell biomarkers that may predict the success or failure of CAR therapy in patients with refractory chronic lymphoblastic leukemia (CLL). These findings open new prospects for improving T cell product manufacturing and the management of patients with CLL undergoing T cell-based therapies.

Publication types

Comment

MeSH terms

Cell- and Tissue-Based Therapy
Humans
Immunotherapy, Adoptive*
Leukemia, Lymphocytic, Chronic, B-Cell / immunology*
Receptors, Antigen, T-Cell / immunology
Receptors, Chimeric Antigen

Substances

Receptors, Antigen, T-Cell
Receptors, Chimeric Antigen